TY - JOUR
AU - M. McGee
AU - K. Chiu
AU - R. Moineddin
AU - A. Sud
A1 - 
AD - Bridgepoint Collaboratory for Research and Innovation, Lunenfeld-Tanenbaum Research Institute, Sinai Health, 1 Bridgepoint Dr, Toronto, ON, M4M 2B5, Canada.; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.; Bridgepoint Collaboratory for Research and Innovation, Lunenfeld-Tanenbaum Research Institute, Sinai Health, 1 Bridgepoint Dr, Toronto, ON, M4M 2B5, Canada. abhimanyu.sud@utoronto.ca.; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. abhimanyu.sud@utoronto.ca.; Humber River Hospital, Toronto, ON, Canada. abhimanyu.sud@utoronto.ca.; Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. abhimanyu.sud@utoronto.ca.
AN - 36652186
BT - Appl Health Econ Health Policy
C5 - Opioids & Substance Use; Financing & Sustainability
CP - 3
DA - May
DO - 10.1007/s40258-022-00787-0
DP - NLM
ET - 20230118
IS - 3
JF - Appl Health Econ Health Policy
LA - eng
PY - 2023
SN - 1175-5652 (Print); 1175-5652
SP - 501
EP - 510+
ST - The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment
T1 - The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment
T2 - Appl Health Econ Health Policy
TI - The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment
U1 - Opioids & Substance Use; Financing & Sustainability
U3 - 10.1007/s40258-022-00787-0
VL - 21
VO - 1175-5652 (Print); 1175-5652
Y1 - 2023
ER -